NGNE   $54.65  3.27% Market Closed After Close 54.4 -0.46%

Neurogene Inc

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 5
Target Price Mean 51
Mean unverified/preliminary 51 / 51
Target Price Low / High 44 / 65
Median / STD DEV 49 / 8.56
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi ActivelyBuy Sell Sell
macd Sell None None
stoch Sell None None
ma20 Sell Sell Sell
ma50 Sell None None
ma100 None Sell None
Candlestick PatternOct. 10, 2024 Bearish Three Inside Down - pattern is a made up of three candlesticks. Big white candlestick appears on the first day in a uptrend. The second day body is engulfed by the body of the first day. A black candlestick on the third day with a lower close than the second day. Considered to be a bearish reversal pattern.
ISIN US64135M1053
ceo Dr. Rachel L. McMinn Ph.D.
Website https://www.neurogene.com
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.